| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.12659/MSM.893619 |
| P8608 | Fatcat ID | release_kjm4xppfurhilohgawsb7cxsje |
| P932 | PMC publication ID | 4523006 |
| P698 | PubMed publication ID | 26210594 |
| P50 | author | Miroslav Zeman | Q44231962 |
| Aleš Žák | Q59195725 | ||
| Marek Vecka | Q59397942 | ||
| Barbora Staňková | Q59613821 | ||
| František Perlík | Q66886683 | ||
| P2093 | author name string | Eva Tvrzická | |
| Róbert Hromádka | |||
| P2860 | cites work | Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A) | Q24297428 |
| The immunobiology of prostanoid receptor signaling in connecting innate and adaptive immunity | Q27021651 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy | Q29616232 | ||
| A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation | Q29619212 | ||
| Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials | Q29622947 | ||
| Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study | Q33592321 | ||
| Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management | Q34181381 | ||
| Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin | Q34190482 | ||
| Niacin: another look at an underutilized lipid-lowering medication | Q34255686 | ||
| The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression | Q34319434 | ||
| Prostaglandins as modulators of immunity | Q34543566 | ||
| Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts | Q68156084 | ||
| Did AIM-HIGH aim too low? | Q82807148 | ||
| Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation | Q83398128 | ||
| A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients | Q85712286 | ||
| Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile. | Q34565247 | ||
| Pharmacological effects of lipid-lowering drugs on circulating adipokines | Q34877922 | ||
| Extended-release niacin or ezetimibe and carotid intima-media thickness. | Q35013008 | ||
| Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia | Q35026444 | ||
| Riboflavin (vitamin B-2) and health | Q35147526 | ||
| Effects of extended-release niacin with laropiprant in high-risk patients | Q35205560 | ||
| Niacin in cardiovascular disease: recent preclinical and clinical developments | Q36084389 | ||
| Marginal vitamin B-6 deficiency decreases plasma (n-3) and (n-6) PUFA concentrations in healthy men and women | Q36235274 | ||
| Vitamin B-6 restriction impairs fatty acid synthesis in cultured human hepatoma (HepG2) cells | Q36593109 | ||
| Safety considerations with niacin therapy. | Q36763069 | ||
| Dietary nutrient intake and metabolic syndrome risk in Chinese adults: a case-control study | Q37059801 | ||
| Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. | Q37097541 | ||
| Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes | Q37254899 | ||
| Effect of equivalent on-treatment apolipoprotein levels on outcomes (from the AIM-HIGH and HPS2-THRIVE). | Q43815024 | ||
| Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease | Q43834212 | ||
| Statins and the risk of diabetes: evidence from a large population-based cohort study. | Q43884432 | ||
| Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential | Q44489192 | ||
| The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey | Q44564042 | ||
| Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta | Q45146790 | ||
| A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events | Q45229045 | ||
| High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. | Q45232465 | ||
| Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia | Q46727643 | ||
| Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis | Q46810855 | ||
| Is niacin ineffective? Or did AIM-HIGH miss its target? | Q48727881 | ||
| Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline | Q56092268 | ||
| Clofibrate and niacin in coronary heart disease | Q66891546 | ||
| Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid | Q67690736 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | niacinamide | Q192423 |
| hyperlipidemia | Q1079120 | ||
| nicotinic acid | Q134658 | ||
| P304 | page(s) | 2156-2162 | |
| P577 | publication date | 2015-07-25 | |
| P1433 | published in | Medical Science Monitor | Q15756323 |
| P1476 | title | Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place? | |
| P478 | volume | 21 |
| Q41105575 | Effects of an Enriched Extract of Paeoniflorin, a Monoterpene Glycoside used in Chinese Herbal Medicine, on Cholesterol Metabolism in a Hyperlipidemic Rat Model. |
| Q38810790 | Pleiotropic effects of niacin: Current possibilities for its clinical use. |
| Q51776565 | Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule. |
Search more.